普伐他汀对人胰腺癌细胞SW1990的影响及其联合顺铂的抗瘤作用

摘要
图/表
参考文献(16)
相关文章 (15)

全文: PDF (0 KB) HTML (45 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨普伐他汀对人胰腺癌细胞SW1990的作用及其联合顺铂对该细胞增殖的影响。方法采用MTT比色法检测普伐他汀对SW1990细胞生长的抑制作用，采用流式细胞仪测定细胞的周期分布和凋亡率。顺铂、普伐他汀联合顺铂作用细胞48 h后，采用MTT法测定各处理组的OD值，并计算相互作用指数（CI）。结果1、5、10、15、25 μmol/L普伐他汀作用于SW1990细胞24～72 h，随着药物浓度增加和作用时间延长，处理组OD值不同程度下降（P＜0.05），生长抑制率逐渐增大。0、5、15、25 μmol/L普伐他汀处理细胞48 h后，G0/G1期细胞逐渐增多，S期和G2/M期细胞逐渐减少，凋亡率由（2.74±0.92）%增加至（27.85±1.56）%。普伐他汀联合顺铂作用细胞后，两者的CI值均＜1。结论普伐他汀具有抑制胰腺癌细胞SW1990增殖和诱导该细胞凋亡的作用，并可阻滞细胞周期于G1期。普伐他汀联合顺铂对SW1990细胞具有协同抗瘤作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张敏

关键词 ：普伐他汀, 顺铂, 胰腺癌, 增殖, 凋亡, SW1990

Abstract：Objective To study the effects of Pravastatin on human pancreatic cancer cell SW1990 and the influence of combining Pravastatin and Cisplatin on the cells proliferation.Methods Inhibition of Pravastatin on SW1990 cells was measured by MTT colorimetric method,apoptosis rate and distribution of cell cycle were shown by flow cytometry.After the cells were treated with cisplatin,combining Pravastatin with Cisplatin for 48 hours,Proliferation was examined with MTT test,the OD values were computed,the combination index(CI)was calculated.Results SW1990 cells were treated with 1,5,10,15,25 μmol/L Pravastatin for 24 hours to 72 hours,with the increase of drug concentration and the prolongation of time,different levels of OD value in each treatment group decreased(P＜0.05),the growth inhibition rate increased gradually.After the cells were treated with 0,5,15,25 μmol/L Pravastatin for 48 hours,the number of cells in G0/G1phase increased gradually,while the number of cells in S phase and G2/M phase decreased gradually,and the apoptosis rate increased from(2.74±0.92)%to(27.85±1.56)%.The CI values of Cisplatin and Pravastatin were all less than 1 when the cells were treated with two drugs.Conclusion Pravastatin can inhibit the proliferation and induce the apoptosis of SW1990 cells in vitro,and show an arrest of cell cycle in G1phase.Combining Pravastatin with Cisplatin show a synergistic antitumor effect on SW1990 cells.

Key words： Pravastatin Cisplatin Pancreatic cancer Proliferation Apoptosis SW1990

基金资助:河北省科学技术成果（20161314）

作者简介: 张敏（1979-），女，汉族，河北邢台人，硕士，主治医师，研究方向：肿瘤化疗、姑息治疗，专业擅长：肿瘤内科

引用本文:

张敏. 普伐他汀对人胰腺癌细胞SW1990的影响及其联合顺铂的抗瘤作用[J]. 中国当代医药, 2016, 23(31): 4-6转13.
ZHANG Min. Influence of Pravastatin on human pancreatic cancer cell SW1990 and its synergistic antitumor effects with Cisplatin. 中国当代医药, 2016, 23(31): 4-6转13.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2016/V23/I31/4

[1]	Rahib L，Smith BD，Aizenberg R，et al.Projecting cancer incidence and deaths to 2030：the unexpected burden of thyroid，liver，and pancreas cancers in the United States[J]. Cancer Res，2014，74（11）：2913-2921.
[2]	Endo A.A historical perspective on the discovery of statins[J]. Proc Jpn Acad Ser B Phys Biol Sci，2010，86（5）：484-493.
[3]	Kotamaraju S，Williams CL，Kalyanaraman B.Statin-induced breast cancer cell death：role of inducible nitric oxide and arginase-dependent pathways[J].Cancer Res，2012，67（7）：7386-7394.
[4]	Yamazaki H，Suzuki M，Aoki T，et al.Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhitors on ubiquinone levels in rat skeletal muscle and heart：relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells[J].J Atheroscler Thromb，2013，13（1）：295-307.
[5]	Kah J，Wustenberg A，Keller AD，et al.Selective induction of apoptosis by HMG-GOA reductase inhibitors in hepatoma cells and dependence on p53 expression[J].Oncology，2012，28（3）：1077-1083.
[6]	Porfire A，Tomuta I，Muntean D，et al.Optimizing long-circulating liposomes for delivery of simvastatin to colon26 carcinoma cells[J].J Liposome Res，2014，25（4）：261-269.
[7]	Yu X，Pan Y，Ma H，et al.Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells[J].Oncol Res，2013，20（8）：351-357.
[8]	Spampanato C，Sarnataro M，Giordano E，et al.Simvastatin inhib-its cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of Bcl-2 gene expression[J].Int J Oncol，2012，40（4）：935-941.
[9]	Jemal A，Siegel R，Xu J，et al.Cancer statistics，2010[J].CA Cancer J Clin，2010，60（5）：227-300.
[10]	Heberland J，Bertz J，Wolf U，et al.German cancer statistics 2004[J].BMC Cancer，2010，10：52.
[11]	Li D，Xie K，Wolff R，et al.Pancreatic cancer[J].Lancet，2004，363（9414）：1049-1057.
[12]	Rosell R，Carc ereny E，Gervais R，et al.Erlotinib versus standard chemotherapy as first-line treatment for European patie nts with advanced EGFR mutation-positive non-small-cell lung caner（EURTAC）：a multicenter，open-label，randomized phase 3 trial[J].Lancet Oncol，2012，13（3）：239-246.
[14]	Siegel RL，Miller KD，Jemal A.Cancer statistics[J].CA Cancer J Clin，2015，65（1）：5-29.
[13]	Zhou C，Wu YL，Chen G，et al.Erlotinib versus chemotherapy as first-line treatment for pantients with advanced EGFR mutation-positive non-small-cell lung caner（OPTIMAL，CTONG-0802）：a multicentre，open-label，randomized，phase 3 study[J].Lancet Oncol，2011，12（8）：735-742.
[15]	He Z，Mangala LS，Theriot CA，et al.Cell killling and radio-sensitizing effects of at orvastatin in PC-3prostate cancer cells[J].J Radiat Res，2012，53（2）：225-233.
[16]	Martirosyan A，Clendening JW，Goard CA，et al.Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin：potential therapeutic relevance[J].BMC Cancer，2010，10：103.